Abstract. Recent advances in various forms of omics technologies have generated huge amount of data. To fully exploit these data sets that in many cases are publicly available, robust computational methodologies need to be developed to deal with the storage, integration, analysis, visualization, and dissemination of these data. In this paper, we describe some of our research activities in data integration leading to novel knowledge discovery in life sciences. Our multi-strategy approach with integration of prior knowledge facilitates a novel means to identify informative genes that could have been missed by the commonly used methods. Our transcriptomics-proteomics integrative framework serves as a means to enhance the confidence of and also to complement transcriptomics discovery. Our new research direction in integrative data analysis of omics data is targeted to identify molecular associations to disease and therapeutic response signatures. The ultimate goal of this research is to facilitate the development of clinical test-kits for early detection, accurate diagnosis/prognosis of disease, and better personalized therapeutic management.
Introduction
"Omics" refers to the unified study of complex biological systems characterized by high-throughput data generation and analysis [1] . Bioinformatics methods for data storage, dissemination, analysis, and visualization have been developed in response to the substantial challenges posed by the quantity, diversity and complexity of omics data. In parallel, there has been an explosion of online databases and tools for genome annotation and for the analysis of molecular sequences, profiles, interactions, and structures [2, 3] . The next major challenge is to develop computational methods and models to integrate these abundant and heterogeneous data for investigating, and ultimately deciphering complex phenotypes.
DNA sequencing methods and technologies have evolved at a fast pace since the release of the first genome sequence of a free-living organism in the mid 90's [4] . There are currently over 350 eukaryotic genome sequencing projects [5] . Full genome sequencing has been completed in several organisms, including animal, plant, fungus and protist species. Genome annotation is a good example of the integration of multiple computational and experimental data sources [6] . In the human genome, the ENCyclopedia Of DNA Elements (ENCODE) aims to provide additional resolution, and to identify all functional elements, including all protein-coding and non-coding genes, cis-regulatory elements and sequences mediating chromosome dynamics [7] .
Transcriptomics is also an advanced and relatively mature area, for which consensus data analysis methods are emerging [8] . Recent and versatile technologies, including high-density whole-genome oligonucleotide arrays [9] and massively parallel sequencing platforms [10] will likely improve the reliability and depth of genomic, epigenomic and transcriptomic analyses.
Notwithstanding the innovative aspects of technologies and sophisticated computational methods developed, each omics approach has some inherent limits. Ostrowski and Wyrwicz [11] mention that the input data for integration must: i) be complete, ii) be reliable and iii) correlate with the biological effect under investigation.
Although providing a reasonably exhaustive coverage of expressed genes, transcriptome analysis is not particularly reliable, and findings often need to be confirmed by additional experimental validation, e.g. using reverse transcription polymerase chain reaction (RT-PCR). Another common, legitimate concern with transcriptome analysis is that levels of mRNAs do not necessarily correlate with the abundance of matching gene product(s), and may only reveal gene regulation at the level of transcription. Proteomics, on the other hand, provides a more accurate picture of the abundance of the final gene products, but current methods, even with the latest high resolution technologies [12] , are still associated with relatively low sensitivity in protein identification, and dubious reproducibility [13] . The analysis of transcriptomic and proteomic data is an example where data integration has the potential of improving individual omics approaches and overcoming their limitations [14] .
Omics data that can eventually be integrated for the comprehensive elucidation of complex phenotypes include functional gene annotations, gene expression profiles, proteomic profiles, DNA polymorphisms, DNA copy number variations, epigenetic modifications, etc.
In the Knowledge Discovery Group at the Institute for Information Technology of the National Research Council Canada, one of our goals is to develop methods and tools for the integration of omics data. We aim to develop general methods with applications in diverse fields, e.g. the identification of biomarkers and targets in human cancer and the identification of genes associated with quantitative traits to be used in selection and engineering of crop plants. In this paper, different projects from our group are reviewed and approaches are illustrated with applications on biological data.
Integrative approach to informative gene identification from gene expression data

A multi-strategy approach with integration of prior knowledge
Owing to its relatively low cost and maturity, microarray has been the most commonly used technology in functional genomics. One of the fundamental tasks in microarray data analyses is the identification of differentially-expressed genes between two or more experimental conditions (e.g. disease vs. healthy). Several statistical methods have been used in the field to identify differentially expressed genes. Since different methods generate different lists of genes, it is difficult to determine the most reliable gene list and the most appropriate method. To retain the best outcomes of each individual method and to complement the overall result with those that can be missed using only one individual method, we have developed a multi-strategy approach [15] that takes advantage of prior knowledge such as GO annotation, gene-pathway and gene-transcription-factor associations. Fig. 1 is an overview of the proposed multi-strategy approach with prior knowledge integration. Microarray data are first passed through a basic data preprocessing stage (background correction, normalization, data filtering, and missing value handling). The next step is to apply different experimental methods to obtain lists of differentially expressed genes. We then establish a confidence measure to select a set of genes to form the core of our final selection. The remaining genes in the lists form the peripheral set which is subject to exclusion or inclusion into the final selection by similarity searches between the peripheral and the core lists. The similarity searches are based on prior knowledge such as i) biological pathways (based e.g. on the KEGG database) or ii) biological function or process (based on GO annotations) or iii) regulation by similar mechanisms (based on common transcription factors).
Depending on the context, there is a variety of ways to define the confidence measure to form the core and peripheral sets of genes. A unanimous voting scheme could define a simple confidence measure, under which the core consists of genes that are identified by all methods that were applied. Another, less stringent voting scheme is to define the core as the genes that are selected by more than one method.
Microarray Data
Data Preprocessing
Peripheral Genes In this section we describe the application of the proposed methodology to identify defense response genes in plants [16] . When a plant is infected by a biotrophic pathogen, the concentration of salicylic acid (SA) rises dramatically and massive changes in patterns of gene expression occur. The accumulation of SA is needed to trigger different signaling events, which can also be triggered by exogenous spraying of SA on the plants, even in the absence of pathogen. To help establish the role of various transcription factors involved in disease resistance [17, 18] and the regulation of defense genes, a set of microarray experiments were conducted using four genotypes of Arabidopsis thaliana: Columbia wild-type Col-0, mutant npr1, double mutant in all Group I TGA factors, tga1 tga4, and triple mutant in all Group II TGA factors, tga2 tga5 tga6. Triplicate samples were collected before, 1 and 8 hours after SA treatment. Affymetrix Arabidopsis ATH1 (20K probe sets) microarray platform was used in this study. A total of 36 arrays were hybridized. To identify SA-induced genes we identify the differentially-expressed genes for the following 7 pairs of conditions  wild-type @ 8h vs. wild-type @ 0h  npr1 @ 8h vs. wild-type @ 0h  tga1-4 @ 8h vs. wild-type @ 0h  tga2-5-6@ 8h vs. wild-type @ 0h  npr1 @ 8h vs. wild-type @ 8h  tga1-4 @ 8h vs. wild-type @ 8h  tga2-5-6@ 8h vs. wild-type @ 8h
The background subtracted data were processed through global quantile normalization across 36 arrays and filtering. The final list contains 10256 genes. The following is the detail of applying the multi-strategy methodology:
 Four methods were used:
o M1: t-test with fold-change set to 2 and p-value 5% o M2: SAM with fold-change set to 2 and FDR 5% o M3: Rank-Products (RP) with FRD set to 5% o M4: fold-change with threshold set at 1.5  Confidence measure: majority voting model, i.e., genes that were identified by more than one method.  Gene recruitment mechanisms (similarity search):
o Genes in the peripheral set that participate in the same biological pathway as some in the core set o Genes in the peripheral set that have similar promoter characteristics as some in the core set. The methodology identified a list of 2303 core genes and a list of 3522 peripheral genes. Through the similarity search with the aid of prior knowledge, we were able to identify an additional 408 genes from KEGG pathway search, and 198 genes from transcription factor binding site search. The recruitment algorithms uncovered many important SA mediated and other defence genes that could have been missed if single analysis method were used (a partial list is shown in Fig. 3 ). 
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Transcriptomics and proteomics integration: a framework using global proteomic discovery to complement transcriptomics discovery
The transcriptome data generated by microarray or other means can only provide a snapshot of genes involved in a physiological state or a cellular phenotype at mRNA level. Advances in proteomics have allowed high-throughput profiling of expressed proteins to elucidate the intricate protein-protein interactions and various biological systems dealing with the downstream products of gene translation and posttranslational modification. Genome-wide analysis at the protein level is a more direct reflection of gene expression. The consistency between proteomics and transcriptomics can increase our confidence in identification of biomarkers; differences can also reveal additional post-transcriptional regulatory or recover the missed genes by other reasons to complement transcriptomics discovery. In this section we exploit proteomics and transcriptomics in parallel. We developed a framework using global proteomics discovery, as shown in Figure 4 , to enhance the confidence in transcriptomics analysis and to complement the discovery with genes that could have been missed for various reasons such as chemical contamination on the arrays, analysis threshold settings, or genes that were not spotted on the original platform.
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Fig. 4. A transcriptomics and proteomics complementary discovery framework
In the following, we describe an application of the above framework to an experiment to identify EMT-related (Epitherial-to-Mesenchymal Transition) breast cancer biomarkers. The microarray experiments were performed by Biotechnology Research Institute, NRC. This dataset was generated by exposing JM01 mouse cell line [19] to a treatment with the Transforming Growth Factor (TGF-) for 24 hours. TGF-induces an Epithelial-to-Mesenchymal Transition in these cells, a phenomenon characterized by significant morphology and motility changes, which are thought to be critical for tumour progression. The transcriptome changes after 24 hours in TGFtreated vs. non-treated control cells were monitored using Agilent 41K mouse genome array (four technical replicates). The microarray analysis was done using a multistrategy approach as described in [15] . The proteomics experiments were performed by Institute for Biological Sciences, NRC [20] . The global proteomics discovered 13 proteins, which are induced by TGF-, and are mapped to the corresponding transcriptomics results. As shown in Table 1 , the discovery of this group of genes (Clu, Fn, Itga5, Acpp, Itgb5, Itga6, and Tacstd2) by transcriptomics approach were also confirmed by the proteomics approach. The proteomics approach identified additional genes (Actg1, Hnrnpu, Ubqln2, Pttg1ip, Ldlr and Itgb4) that were missed from the transcriptomics approach. 
Integrative data analysis for gene set biomarker and disease target discovery
Complex human diseases occur as a result of multiple genetic alterations and combinations of environmental factors. The integrative analysis of multiple omics data sources is a promising strategy for deciphering the molecular basis of disease and for the discovery of robust molecular signatures for disease diagnosis/prognosis [11] . Oncology is the field of research where biomarker discovery is most advanced. Various types of biomarkers have been identified for use in prognostic and eventually provide patients with personalized treatment [21, 22] . Emerging themes in cancer research include i) the exploitation of panels of biomarkers for successful translation of discoveries into clinical applications [23] and ii) the understanding of cancer at the pathway-level [24] . We believe that there is a considerable potential for disease target discovery and biomarker identification in shifting from single gene to metabolic pathway (or other functional gene set) analysis of omics data. Moreover, having identified disease targets in their biological context may be useful in further steps of the commercialization process.
Gene Set Analysis (GSA) approaches intend to identify differentially expressed sets of functionally related genes [25] . Most GSA methods start with a list of differentially expressed genes, and use contingency statistics to determine if the proportion of genes from a given set is surprisingly high [26] . Gene Set Enrichment Analysis is a popular alternative [27] . It tests whether the rank of genes ordered according to P-values differs from a uniform distribution. Goeman and Bühlmann recently reviewed existing GSA methods, and strongly recommended the use of selfcontained methods [28] . We are currently developing and testing statistical methods for GSA analysis of cancer expression profiles. The Kyoto Encyclopedia of Genes and Genomes (KEGG) [29] and the Gene Ontology (GO) [30] are used to group genes into sets, and differential expression is assessed for gene sets rather than individual genes. Future developments will include integration of pathway and ontology knowledge in combination with transcriptomics and proteomics analysis of tumor samples.
Conclusion
One of the major challenges in dealing with today's omics data is its proper integration through which various forms of useful knowledge can be discovered and validated. In this paper we discussed our attempts in integrating omics data and introduced case studies in which various forms of omics data have been used to complement each other for knowledge discovery and validation. Among methods developed, a novel multi-strategy approach showed some interesting results in the analysis of transcriptomics and proteomics data, which also includes biological experimental validation. Until now, all of our integrated case studies have resulted in interesting discoveries, among which are cases where using a single form of biological data would have resulted in missing some valuable information. This is evident from our transcriptomics/proteomics integration example explained in this paper. Our ultimate goal is to develop platforms that facilitate development of clinical test kits that are based on multiple sources of omics data.
